MacDonald Kelly, Chief Accounting Officer, subtracted 987 shares of Ironwood Pharmaceuticals, Inc. (IRWD) from its portfolio at the rate of $11.00 per share valuing $10,857 on Nov 08. The insider left behind 78,337 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $12.26, with a 2nd Resistance Point sitting at $12.45. Meanwhile, this company’s stock has a 1st Support Level at $11.78 and a 2nd Support Level at $11.49. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Ironwood Pharmaceuticals, Inc. (IRWD) was $12.06. Ironwood Pharmaceuticals, Inc. (IRWD) stock has lost -$0.14, or -0.78%, in the past five days. In the last full month, these shares have gained $1.69, or 16.35%. In the past three months, this stock’s price has risen by $2.79, or 30.15%. This year-to-date, Ironwood Pharmaceuticals, Inc. (IRWD) shares have gained $1.70, or 16.46%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Ironwood Pharmaceuticals, Inc. (IRWD) stock, 100% of short-term indicators suggest that these shares are a “ Buy .” Looking further ahead, 50% of long-term indicators suggest that this stock is a “ Buy .”
With 156,818 K shares outstanding, this company currently has a market capitalization of $1,861,430K. Ironwood Pharmaceuticals, Inc. (IRWD) generates $346,640 K in annual sales, amounting to annual net income of -$282,370 K. This stock has generated a 1-Year Total Return of -12.57%, a 3-Year Total Return of -22.11%, and a 5-year Total Return of -20.87%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 09/19, Ironwood Pharmaceuticals, Inc. (IRWD) reported earnings of $0.40 per share. Wall Street analysts, on average, were expecting the company to report earnings of $0.10 per share, representing a 0.30 difference and 300.00% surprise.
For the current fiscal quarter, which is set to end in 12/2019, the average earnings estimate is $0.22 per share. This estimate came from a total of 4 Wall Street Analysts. Of those market experts, the high estimate was $0.27 and the low estimate was $0.19. In the year-ago quarter, Ironwood Pharmaceuticals, Inc. (IRWD) generated per-share earnings of -$0.02. If the analysts are correct about the current quarter’s earnings, the growth will be +1,200.00%.
Turning our focus now to insider trading activity, there have been 1 purchases (1,692 shares in total) and 4 sale (2,497 shares in total) in the last 3 months. In the last 6 months, there have been 6 insider buys amounting to 250,759 shares and 9 insider sales amounting to 246,209 shares. In the past full year, 37 insider purchases were made (involving 1,139,612 shares) and 51 insider sell-offs equivalent to 3,253,864 shares.
Moving onto liquidity, Ironwood Pharmaceuticals, Inc. (IRWD) has a Current Ratio of 2.23, a Quick Ratio of 2.23 and a Cash Ratio of 1.46. Looking at this company’s capital structure, its Total Debt to Total Capital is 190.26, and its Total Debt to Total Assets is now 124.66. Looking even further ahead into the future, its Long-Term Debt to Equity is -2.71.